Like most websites The Translational Scientist uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Disease Area Infectious diseases

Fighting the Flu

The antiviral drugs used to treat influenza can lose their effectiveness over time, as the RNA virus spontaneously mutates to evade their mechanisms of action. As a stark example, amantadine, an M2 ion channel inhibitor, is not currently recommended for use in the USA by the Centers of Disease Control and Prevention because of widespread resistance in circulating influenza A viruses.

Now, researchers in Seoul and Daejeon, South Korea, believe they have found a promising new antiviral agent after screening a chemical library of over 2000 synthetic compounds (1). Salinomycin demonstrated potent inhibitory potential against both influenza A and B by seemingly blocking the uptake of viral nuclear protein (NP) into the host cell nucleus and thus restricting the viruses’ ability to replicate effectively. Salinomycin also appeared to block the activity of M2 – but through a different mechanism of action to amantadine.

"Spanish Flu" - The Influenza pandemic lasted for two years from 1918, and effected five-hundred million people worldwide; killing up to one-hundred million of them. It remains the deadliest flu outbreak in recorded history.

The drug produced similar antiviral effects in influenza A virus-infected mouse models. And when used in combination with oseltamivir phosphate (OSV-P) – a neuradamidase inhibitor – its efficacy was further improved. When it comes to translation into the clinic, the researchers are “confident” that a chemical derivative of salinomycin could be developed as an “adjuvant antiviral therapy to treat influenza infections resistant or less sensitive to existing drugs.”

Enjoy our FREE content!

Log in or register to gain full unlimited access to all content on the The Translational Scientist site. It’s FREE and always will be!


Or register now - it’s free and always will be!

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts

Or Login via Social Media

By clicking on any of the above social media links, you are agreeing to our Privacy Notice.

  1. Y Jang et al. “Salinomycin Inhibits Influenza Virus Infection by Disrupting Endosomal Acidification and Viral Matrix Protein 2 Function,” J Virol, 92; 24 p1441-18. (2018) PMID: 30282713

About the Author

Jonathan James

As an assistant editor for The Translational Scientist, I can combine two of my passions; translational science research and science communication. Having thrown myself into various editing and other science communication gigs whilst at University I came to realise the importance of good quality content that delivers in an exciting and engaging way.

Register to The Translational Scientist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts